ReviewExpert opinion on therapeutic patents2014
Protein chaperones: a composition of matter review (2008 - 2013).
Review in Expert opinion on therapeutic patents, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Metabolic engineering for single-cell protein production from renewable feedstocks and its applications.Advanced biotechnology · 2024Review
- Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy.Molecules (Basel, Switzerland) · 2022Article
- Molecular chaperone Hsp90 protects KCBP from degradation by proteasome in Dunaliella salina cells.Folia microbiologica · 2021Article
- Structure-guided approaches to targeting stress responses in human fungal pathogens.The Journal of biological chemistry · 2020Review
- A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.Cold Spring Harbor perspectives in biology · 2020Review
- A high throughput substrate binding assay reveals hexachlorophene as an inhibitor of the ER-resident HSP70 chaperone GRP78.Bioorganic & medicinal chemistry letters · 2019Article
- Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus.Nature communications · 2019Article
- Etoposide-Induced Apoptosis in Cancer Cells Can Be Reinforced by an Uncoupled Link between Hsp70 and Caspase-3.International journal of molecular sciences · 2018Article
- Effects of Inhibitors on Hsp90's Conformational Dynamics, Cochaperone and Client Interactions.Chemphyschem : a European journal of chemical physics and physical chemistry · 2018Article
- Targeting the Proteostasis Network for Mycobacterial Drug Discovery.ACS infectious diseases · 2018Review
- Sensitizing tumor cells to conventional drugs: HSP70 chaperone inhibitors, their selection and application in cancer models.Cell death & disease · 2018Article
- Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-BioMed research international · 2018Article
- Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2017Article
- Article
- Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.Molecular and clinical oncology · 2016Article
- Protein Folding and Mechanisms of Proteostasis.International journal of molecular sciences · 2015Review
- Proteotoxicity and cardiac dysfunction.Circulation research · 2015Review
- Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.Oncotarget · 2015Article
- Ganetespib: research and clinical development.OncoTargets and therapy · 2015Review
- Protein folding in the cell, from atom to organism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionHeat shock proteins (Hsps) are proteins with important functions in regulating disease phenotypes. Historically, Hsp90 has first received recognition as a target in cancer, with consequent efforts extending its potential role to other diseases. Hsp70 has also attracted interest as a therapeutic target for its role as a co-chaperone to Hsp90 as well as its own anti-apoptotic roles. AREAS COVERED: Herein, patents from 2008 to 2013 are reviewed to identify those that disclose composition of matter claimed to inhibit Hsp90 or Hsp70. EXPERT OPINION: For Hsp90, there has been considerable creativity in the discovery of novel pharmacophores that fall outside the three initially discovered scaffolds (i.e., ansamycins, resorcinols and purines). Nonetheless, much of the patent literature appears to build on previously reported structure activity relationship through slight modifications of Hsp90 inhibitor space by finding weaknesses in existing patents. The major goal of future development of Hsp90 inhibitors is not necessarily identifying better molecules but rather understanding how to rationally use these agents in the clinic. The development of Hsp70 inhibitors has lagged behind. It will require a more concerted effort from the drug discovery community in order to begin to realize the potential of this target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.